2 studies were found.

1.		Recruiting	Provenge® Immunotherapy Vaccine for the Treatment of Metastatic Prostate Cancer after Failing Hormone Therapy Condition: Prostate Cancer
2.		No longer recruiting	Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy Conditions: stage IV prostate cancer; adenocarcinoma of the prostate; recurrent prostate cancer